

AMGEN: Innovation + Emerging Market – A Balanced Approach!

<https://marketpublishers.com/r/A26382FA926EN.html>

Date: May 2012

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: A26382FA926EN

Abstracts

Acquisition in 2012 of Micromet (MITI) and KAI pharma (pvt., US based) has boosted Amgen's (AMGN) pipeline, while Mustafa Nevzat pharma (MN pharma, pvt., Turkey) is a strategic move to increase its presence in the growing emerging/ international markets. Data at ASCO '12 increases confidence in its pipeline and acquisitions- Positive data of Blinatumomab (Pivotal PhII, rrALL), Rilotumomab (AMG 102, cMET/HGF Mab PhII, gastric Cancer), and denosumab (in subset CRPC pts). Denosumab is the key growth driver for next two to three year. What more upside, we expect from launched drugs and the pipeline... For more details, please read our report released on May 29th, 2012 on AMGN, titled "Innovation + Emerging Market – A Balanced Approach"

Contents

COMPANIES MENTIONED

AMGEN

I would like to order

Product name: AMGEN: Innovation + Emerging Market – A Balanced Approach!

Product link: <https://marketpublishers.com/r/A26382FA926EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A26382FA926EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970